CO5601020A2 - OX-AZABICICLIC COMPOUNDS - Google Patents
OX-AZABICICLIC COMPOUNDSInfo
- Publication number
- CO5601020A2 CO5601020A2 CO04082792A CO04082792A CO5601020A2 CO 5601020 A2 CO5601020 A2 CO 5601020A2 CO 04082792 A CO04082792 A CO 04082792A CO 04082792 A CO04082792 A CO 04082792A CO 5601020 A2 CO5601020 A2 CO 5601020A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- group
- hydrogen
- independently
- represent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
1.- Un compuesto seleccionado de aquellos de la fórmula (I):caracterizado porque:? X1, X2 y X3, independientemente uno de otro, representan un átomo de nitrógeno o un grupo -CR3 en donde R3 representa un grupo seleccionado de hidrógeno, alquilo (de C1-C6), amino, monoalquilamino (de C1-C6), dialquilamino (de C1-C6), hidroxi, alcoxi (de C1-C6) y halógeno, con la condición de que no más de dos de los grupos X1, X2 y X3 simultáneamente representen un átomo de nitrógeno,? G1 representa un grupo seleccionado de aquellos de lasfórmulas (i/a) e (i/b): en donde:- el átomo de carbono con el número 2 está unido al grupo N-R1 del anillo,- R4 y R5, idénticos o diferentes, independientemente uno de otro, representan un grupo seleccionado de hidrógeno, alquilo (de C1-C6), arilo, arilalquilo (de C1-C6), cicloalquilo, cicloalquilalquilo (de C1-C6), heteroarilo, heteroarilalquilo (de C1-C6), heterocicloalquilo, y heterocicloalquilalquilo (de C1-C6),- R4 representa un grupo seleccionado de: hidrógeno, trifluorometilo, OR7, NR7R8, en donde R7 y R8, idénticos o diferentes independientemente uno de otro, representan hidrógeno o alquilo (de C1-C6), alquilo (de C1-C6), alquenilo (de C2-C6), alquinilo (de C2-C6), arilo, arilalquilo (de C1-C6), cicloalquilalquilo (de C1-C6), heteroarilo, heteroarilalquilo (de C1-C6), heterocicloalquilo, y heterocicloalquilalquilo (de C1-C6), estos grupos son optativamente sustituidos por uno o más grupos, que pueden ser idénticos o diferentes independientemente uno de otro, seleccionados de halógeno, amino, monoalquilamino (de C1-C6), dialquilamino (de C1-C6), cada grupo alquilo es idéntico o diferente independientemente uno de otro, ...1.- A compound selected from those of the formula (I): characterized in that :? X1, X2 and X3, independently of each other, represent a nitrogen atom or a -CR3 group in which R3 represents a group selected from hydrogen, (C1-C6) alkyl, amino, monoalkylamino (from C1-C6), dialkylamino (from C1-C6), hydroxy, alkoxy (from C1-C6) and halogen, with the proviso that no more than two of the groups X1, X2 and X3 simultaneously represent a nitrogen atom ,? G1 represents a group selected from those of the formulas (i / a) and (i / b): where: - the carbon atom with the number 2 is attached to the N-R1 group of the ring, - R4 and R5, identical or different, independently of one another, represent a group selected from hydrogen, (C1-C6) alkyl, aryl, arylalkyl (from C1-C6), cycloalkyl, cycloalkylalkyl (from C1-C6), heteroaryl, heteroarylalkyl (from C1-C6 ), heterocycloalkyl, and heterocycloalkylalkyl (from C1-C6), - R4 represents a group selected from: hydrogen, trifluoromethyl, OR7, NR7R8, wherein R7 and R8, identical or different independently of each other, represent hydrogen or (C1-alkyl) -C6), (C1-C6) alkyl, alkenyl (from C2-C6), alkynyl (from C2-C6), aryl, arylalkyl (from C1-C6), cycloalkylalkyl (from C1-C6), heteroaryl, heteroarylalkyl ( of C1-C6), heterocycloalkyl, and heterocycloalkylalkyl (of C1-C6), these groups are optionally substituted by one or more groups, which may be identical or different independently from each other, selected from halogen, amino, monoalkylamino (from C1-C6), dialkylamino (from C1-C6), each alkyl group is identical or different independently from each other, ...
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2002/003240 WO2003076416A1 (en) | 2002-03-08 | 2002-03-08 | Oxo azabicyclic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5601020A2 true CO5601020A2 (en) | 2006-01-31 |
Family
ID=27798761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO04082792A CO5601020A2 (en) | 2002-03-08 | 2004-08-25 | OX-AZABICICLIC COMPOUNDS |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1492775A2 (en) |
JP (1) | JP2005526070A (en) |
KR (1) | KR20040095270A (en) |
CN (1) | CN1738806A (en) |
AP (1) | AP2004003125A0 (en) |
AR (1) | AR039562A1 (en) |
AU (2) | AU2002249275A1 (en) |
BR (1) | BR0308280A (en) |
CA (1) | CA2478706A1 (en) |
CO (1) | CO5601020A2 (en) |
EA (1) | EA200401053A1 (en) |
EC (1) | ECSP045278A (en) |
IL (1) | IL163818A0 (en) |
IS (1) | IS7414A (en) |
MA (1) | MA27183A1 (en) |
MX (1) | MXPA04008681A (en) |
NO (1) | NO20044041L (en) |
OA (1) | OA12782A (en) |
PA (1) | PA8568501A1 (en) |
PE (1) | PE20031018A1 (en) |
PL (1) | PL372622A1 (en) |
SV (1) | SV2003001495A (en) |
TN (1) | TNSN04169A1 (en) |
UY (1) | UY27700A1 (en) |
WO (2) | WO2003076416A1 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PA8539501A1 (en) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | TRIAZOLO COMPOUNDS AS MMP INHIBITORS |
US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
CA2495293A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors |
PA8578101A1 (en) | 2002-08-13 | 2004-05-07 | Warner Lambert Co | HETEROBIARILO DERIVATIVES AS METALOPROTEINASE IN MATRIX INHIBITORS |
WO2004014384A2 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
WO2004014375A2 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
CA2497656A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors |
EP1537098A1 (en) | 2002-08-13 | 2005-06-08 | Warner-Lambert Company LLC | Monocyclic derivatives as matrix metalloproteinase inhibitors |
WO2004014880A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Chromone derivatives as matrix metalloproteinase inhibitors |
AU2003253186A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
WO2004014923A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
WO2004014378A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
WO2005016926A1 (en) * | 2003-08-19 | 2005-02-24 | Warner-Lambert Company Llc | Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors |
DE10360835A1 (en) * | 2003-12-23 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New bicyclic imidazole derivatives are dipeptidylpeptidase-IV inhibitors useful to treat e.g. arthritis, obesity, allograft transplantation and calcitonin-induced osteoporosis |
ZA200609259B (en) * | 2004-04-30 | 2008-07-30 | Takeda Pharmaceutical | Heterocyclic amide compound and use thereof as an mmp-13 inhibitor |
KR20070028536A (en) * | 2004-06-15 | 2007-03-12 | 아스트라제네카 아베 | Substituted quinazolones as anti-cancer agents |
WO2008043087A2 (en) | 2006-10-05 | 2008-04-10 | Cv Therapeutics, Inc. | Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors |
WO2012052451A1 (en) | 2010-10-18 | 2012-04-26 | Merz Pharma Gmbh & Co. Kgaa | Metabotropic glutamate receptor modulators |
CN103524431B (en) * | 2013-09-24 | 2016-01-13 | 西安交通大学 | 3-benzyl-4-quianzolinones and synthetic method thereof and application |
JO3512B1 (en) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | Quinoxaline derivatives useful as fgfr kinase modulators |
LT3353164T (en) | 2015-09-23 | 2022-01-25 | Janssen Pharmaceutica, N.V. | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
JP6898919B2 (en) | 2015-09-23 | 2021-07-07 | ヤンセン ファーマシューティカ エヌ.ベー. | New compound |
FR3046793B1 (en) * | 2016-01-14 | 2018-01-05 | Les Laboratoires Servier | NOVEL PHOSPHINAN DERIVATIVES AND AZAPHOSPHINANES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002513394A (en) * | 1996-12-17 | 2002-05-08 | イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー | Fungicidal quinazolinones |
PA8539401A1 (en) * | 2001-02-14 | 2002-10-28 | Warner Lambert Co | QUINAZOLINAS AS INHIBITORS OF MMP-13 |
PA8539301A1 (en) * | 2001-02-14 | 2002-09-30 | Warner Lambert Co | INHIBITORS OF THE METALOPROTEINASE OF THE MATRIX |
-
2002
- 2002-03-08 WO PCT/EP2002/003240 patent/WO2003076416A1/en not_active Application Discontinuation
- 2002-03-08 AU AU2002249275A patent/AU2002249275A1/en not_active Abandoned
-
2003
- 2003-03-04 SV SV2003001495A patent/SV2003001495A/en not_active Application Discontinuation
- 2003-03-06 UY UY27700A patent/UY27700A1/en not_active Application Discontinuation
- 2003-03-06 MX MXPA04008681A patent/MXPA04008681A/en unknown
- 2003-03-06 BR BR0308280-6A patent/BR0308280A/en not_active IP Right Cessation
- 2003-03-06 AP APAP/P/2004/003125A patent/AP2004003125A0/en unknown
- 2003-03-06 PL PL03372622A patent/PL372622A1/en not_active Application Discontinuation
- 2003-03-06 CN CNA038048752A patent/CN1738806A/en active Pending
- 2003-03-06 AU AU2003212307A patent/AU2003212307A1/en not_active Abandoned
- 2003-03-06 EA EA200401053A patent/EA200401053A1/en unknown
- 2003-03-06 PE PE2003000218A patent/PE20031018A1/en not_active Application Discontinuation
- 2003-03-06 KR KR10-2004-7013994A patent/KR20040095270A/en not_active Application Discontinuation
- 2003-03-06 WO PCT/EP2003/002277 patent/WO2003076417A2/en not_active Application Discontinuation
- 2003-03-06 CA CA002478706A patent/CA2478706A1/en not_active Abandoned
- 2003-03-06 JP JP2003574636A patent/JP2005526070A/en not_active Withdrawn
- 2003-03-06 AR ARP030100749A patent/AR039562A1/en not_active Application Discontinuation
- 2003-03-06 IL IL16381803A patent/IL163818A0/en unknown
- 2003-03-06 EP EP03708181A patent/EP1492775A2/en not_active Withdrawn
- 2003-03-06 OA OA1200400234A patent/OA12782A/en unknown
- 2003-03-06 PA PA20038568501A patent/PA8568501A1/en unknown
-
2004
- 2004-08-19 IS IS7414A patent/IS7414A/en unknown
- 2004-08-25 CO CO04082792A patent/CO5601020A2/en not_active Application Discontinuation
- 2004-08-31 MA MA27842A patent/MA27183A1/en unknown
- 2004-09-03 EC EC2004005278A patent/ECSP045278A/en unknown
- 2004-09-03 TN TNP2004000169A patent/TNSN04169A1/en unknown
- 2004-09-24 NO NO20044041A patent/NO20044041L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1492775A2 (en) | 2005-01-05 |
TNSN04169A1 (en) | 2007-03-12 |
PA8568501A1 (en) | 2003-12-19 |
AU2002249275A1 (en) | 2003-09-22 |
UY27700A1 (en) | 2003-10-31 |
AU2003212307A1 (en) | 2003-09-22 |
BR0308280A (en) | 2004-12-28 |
AP2004003125A0 (en) | 2004-09-30 |
CA2478706A1 (en) | 2003-09-18 |
EA200401053A1 (en) | 2005-04-28 |
PL372622A1 (en) | 2005-07-25 |
WO2003076417A3 (en) | 2003-11-13 |
ECSP045278A (en) | 2004-10-26 |
IS7414A (en) | 2004-08-19 |
NO20044041L (en) | 2004-10-07 |
MXPA04008681A (en) | 2004-12-06 |
WO2003076416A1 (en) | 2003-09-18 |
WO2003076417A2 (en) | 2003-09-18 |
OA12782A (en) | 2006-07-10 |
SV2003001495A (en) | 2003-11-04 |
JP2005526070A (en) | 2005-09-02 |
IL163818A0 (en) | 2005-12-18 |
PE20031018A1 (en) | 2004-01-09 |
MA27183A1 (en) | 2005-01-03 |
KR20040095270A (en) | 2004-11-12 |
CN1738806A (en) | 2006-02-22 |
AR039562A1 (en) | 2005-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5601020A2 (en) | OX-AZABICICLIC COMPOUNDS | |
ECSP034730A (en) | QUINAZOLINAS AS INHIBITORS OF MMP-13 | |
CO5580747A2 (en) | N-ADAMANTILMETILO DERIVATIVES AND INTERMEDIARIES AS PHARMACEUTICAL COMPOSITIONS AND PROCESSES FOR THEIR PREPARATION | |
ES2120535T3 (en) | CROSSLINKING AGENTS WITH CARBAMATE TRIFUNCTIONALITY. | |
CO5601018A2 (en) | DERIVATIVES OF N-FENIL-2-PIRIMIDIN-AMINA | |
CO5560573A2 (en) | ACTIVE DERIVATIVES OF AMINO-FTALAZINONA AS QUINASE INHIBITORS, PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
ATE338461T1 (en) | PYRAZOLEPYRIMIDE INFUNGICIDES | |
AR049784A1 (en) | SUBSTITUTED DERIVATIVES OF MORFOLINA AND TIOMORFOLINA | |
MY138145A (en) | Thienopyrimidinediones and their use in the modulation of autoimmune disease | |
CO5690643A2 (en) | TRIAZA-ESPIROPIPERIDINE DERIVATIVES FOR USE AS GLYT-1 INHIBITORS IN THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | |
PE20010211A1 (en) | THIAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT PROTEIN KINASES | |
ES2193839B1 (en) | NEW DERIVATIVES OF 6-PHENYLDIHYDROPIRROLPIRIMIDINDIONA. | |
NO20052976D0 (en) | Phosphodiesterase-4 inhibitors. | |
ES2571779T3 (en) | Nicotinamide-based kinase inhibitors | |
AR033379A1 (en) | DIFENILUREA COMPOUNDS, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
EE9800266A (en) | Isoquinolines used as analgesics | |
ATE360045T1 (en) | POLYCARBONATE COMPOSITIONS | |
HUP0402227A2 (en) | Phenyl substituted triazoles and their use as selective inhibors of akl5 kinase and pharmaceutical compositions containing the compounds | |
CO5690648A2 (en) | NEW ANALOGS OF ACID 2´, 5´-OLIGOADENILICO | |
UA86013C2 (en) | Aryl alkyl carbamate derivatives production and use thereof in therapy | |
PA8575001A1 (en) | FLUOROBENZAMIDS AS MAOB INHIBITORS | |
ES2106185T3 (en) | 3-CARBOXIESTEROIDS 17-BETA-SUBSTITUTED NOT SATURATED. | |
AR034585A1 (en) | NEW SUBSTITUTED CYAN DIHYDROPIRIMIDINE COMPOUNDS AND THEIR USE FOR TREATMENT OF MATTERS | |
CO5550437A2 (en) | CHEMICAL COMPOUNDS | |
PE20040750A1 (en) | DERIVATIVES OF N- (1-ACETYLPIPERIDIN-4-IL) -4-BENZIDRIL-2-ISOPROPILPIPERAZIN-1-CARBOXAMIDE AS INHIBITORS OF 17BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |